Genmab — Oktober 2020
-
STOCKHOLM (Nyhetsbyrån Direkt) Johnson & Johnson, en amerikansk tillverkare av hälso- och sjukvårdsprodukter, spår en försäljning för helåret 2020 om 82,0-82,8 miljarder dollar.
Det framgår av delårsrapporten.
Bolaget förväntade sig tidigare en försäljning mellan 81,0 och 82,5 miljarder dollar. -
Ok. You may be right. In Denmark we see an increase in numbers (infected, which is also due to the extensive testing, and hospitalised people, both which seem to be moving in the right direction at the moment. In addition people spend less time in the hospitals with the disease than they did at the earlier stages. This due to better treatment, but it also seems like the segment of people in the hospitals is different this time around (that can of course change).
-
Indeed, but other countries also came into a hold the first time around, and the saIe is still on track. I must admit that I don't see the big difference compared to Q1/Q2, other than everyone being better prepared. I hope that I am right and you are wrong - primarily for the patients` sake!
-
-
På baggrund af dagens dara tal hæver Jefferies "bunden" på den negative effekt patentslagsmål mellem JnJ og Genmab, vil have på Genmab' værdiansættelse. Nu "blot" - 15 % mod tidligere - 25 %, såfremt sagen ikke falder ud til Genmabs fordel
-
-
Sry for at bypasse nyhederne her på PI. Opfordrer alle til at om udforske PI og alle de nye feeds der implementeres her. On-place-to-go supermarked
-
Tak LLI..Jeg laver snart en introduktionsvideo.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind